Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
A 14-day study of Racivir when used in combination in HIV-Infected Males
This study is currently recruiting patients.
Sponsored by: | Pharmasset |
---|---|
Information provided by: | Pharmasset |
Purpose
The purpose of this study is to evaluate Racivir. The safety, most effective dosage, and how the body reacts to Racivir will be studied.
Condition | Treatment or Intervention | Phase |
---|---|---|
HIV Infections |
Drug: Racivir |
Phase I |
MedlinePlus related topics: AIDS
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Pharmacokinetics Study
Expected Total Enrollment: 18
Study start: June 2002;
Study completion: December 2002
The study is a 14-day study with a 21-day follow-up period. During the 14-days of active study period, participants will receive Racivir once daily in combination with efavirenz and stavudine. Following the administration of the first and last dose of study medication, patients will remain in the clinic overnight. During the study there will be medical and medication histories taken, physical examinations, vital sign measurements, EKGs, and routine clinical laboratory tests.
Eligibility
Ages Eligible for Study: 18 Years - 45 Years, Genders Eligible for Study: Male
Criteria
Inclusion Criteria
Subjects may be eligible to participate if they:
Exclusion Criteria
Subjects may not participate if they:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |